OrthoPediatrics (KIDS) Q2 FY26 earnings call

OrthoPediatrics achieved record patient impact and adjusted EBITDA in Q2 FY26, driven by strong performance in trauma and deformity and OPSB, alongside healthy international growth. Management raised full-year revenue guidance, expressing confidence in their strategy and the early contributions from their multi-year product launch super cycle, which is expected to drive sustained growth, margin expansion, and improved capital efficiency. The company is focused on balancing profitable revenue growth with disciplined capital allocation, leading to a significant improvement in free cash flow usag